Cargando…
Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
BACKGROUND: Thyroid dysfunction has not been previously reported in clinical trials of selective fibroblast growth factor receptor (FGFR) inhibitors including AZD4547. Herein, we report a case of worsening hypothyroidism in a patient with advanced urothelial cancer treated with AZD4547. CASE PRESENT...
Autores principales: | Ahn, Jeffrey, Moyers, Justin, Wong, John, Hsueh, Chung-Tsen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379924/ https://www.ncbi.nlm.nih.gov/pubmed/30820365 http://dx.doi.org/10.1186/s40164-019-0130-4 |
Ejemplares similares
-
Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
por: Macklis, Paul, et al.
Publicado: (2020) -
Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate
por: Qian, Justin, et al.
Publicado: (2022) -
Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor
por: Patel, Saagar N., et al.
Publicado: (2022) -
Serous Retinopathy Associated With Combination MEK and Fibroblast Growth Factor Receptor Inhibitor
por: Day, H. Russell, et al.
Publicado: (2023) -
Novel parameter for cancer chemosensitivity to fibroblast growth factor receptor inhibitors
por: Kitano, Shoichi, et al.
Publicado: (2022)